Our results are along with those presented by Del Re et al.,14 in which they describe that PIK3CAm detection in liquid biopsy correlates with a poorer PFS in population with metastatic BC undergoing treatment with CDK4/6 inhibitors (7.44 vs. 12.9 months, p = 0.01). This evidence concerns the gene CDK4 and breast cancer.